DA
ABBV icon

Dover Advisors’s AbbVie ABBV Stock Holding History

Dover Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.59M Buy
6,944
+204
+3% +$43.9K 0.65% 44
2026
Q1 		$1.47M Sell
6,740
-204
-3% -$45.3K 0.61% 46
2025
Q4 		$1.59M Buy
6,944
+48
+0.7% +$10.9K 0.61% 47
2025
Q3 		$1.6M Sell
6,896
-7
-0.1% -$1.43K 0.64% 47
2025
Q2 		$1.28M Sell
6,903
-375
-5% -$69.7K 0.56% 48
2025
Q1 		$1.52M Sell
7,278
-286
-4% -$55.6K 0.66% 43
2024
Q4 		$1.34M Hold
7,564
– – 0.77% 41
2024
Q3 		$1.49M Sell
7,564
-585
-7% -$109K 0.85% 38
2024
Q2 		$1.4M Sell
8,149
-99
-1% -$16.4K 0.86% 37
2024
Q1 		$1.5M Buy
8,248
+2,045
+33% +$352K 1.03% 30
2023
Q4 		$961K Sell
6,203
-1,390
-18% -$203K 1.26% 25
2023
Q3 		$1.13M Sell
7,593
-264
-3% -$38.8K 1.15% 30
2023
Q2 		$1.06M Sell
7,857
-410
-5% -$60.1K 0.94% 32
2023
Q1 		$1.32M Buy
8,267
+1,150
+16% +$176K 1.27% 27
2022
Q4 		$1.15M Buy
+7,117
New +$1.09M 1.24% 26

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dover Advisors's ABBV Position: Q2 2026 in Review

Dover Advisors increased its AbbVie (ABBV) stake by 3% in Q2 2026, buying an estimated $43.9K and bringing the position to 6,944 shares worth $1.59M. The position accounts for 0.65% of the portfolio, ranked #44.

Dover Advisors first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.6M in Q3 2025. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Dover Advisors held 6,944 shares of AbbVie worth $1.59M as of Q2 2026.
  • Dover Advisors bought 204 AbbVie shares in Q2 2026, an estimated $43.9K.
  • AbbVie made up 0.65% of Dover Advisors's portfolio in Q2 2026, its #44 holding.
  • Dover Advisors first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
  • Dover Advisors's AbbVie position peaked at $1.6M in Q3 2025.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Dover Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.